Chemotherapy-induced cognitive impairment in hematological malignancies

Howlader N, Noone AM, Krapcho M, et al. (2014): SEER cancer statistics review, 1975-2011, National Cancer Institute.

VT DV, Lawrence TS, Rosenberg SA. Cancer: principles and practice of oncology. 10th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2015. p. 1526–51.

Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–4.

MacDonald V. Chemotherapy: managing side effects and safe handling. The Canadian Veterinary Journal. 2009;50(6):665–8.

Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Results of a prospective, randomized, longitudinal trail. Cancer. 2004;100(11):2292–9.

Bradley CJ, Neumark D, Bednarek HL, Schenk M. Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. Journal of Health Economics. 2005;24:137–60.

Koppelmans V, Breteler MM, Boogerd W, et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal of Clinical Oncology. 2012;30:1080–6.

ReidArndt SA, Hsieh C, Perry MC. Neuropsy-chological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology. 2010;19:535–44.

Dubruille S, Libert Y, Roos M, et al. Identification of clinical parameters predictive of 1-year survival using two geriatric tools in clinically fit older patients with hematological malignancies: major impact of cognition. Journal of Geriatric Oncology. 2015;6:362–9.

Abdel Rahman T, El Gaafary M. Montreal cognitive assessment Arabic version: reliability and validity prevalence of mild cognitive impairment among elderly attending geriatric clubs in Cairo. Geriatrics and gerontology international. 2009. https://doi.org/10.1111/-j.1447-05940.2008.00509.x .

Geissler K, Koller E, Hubmann E, Niederwieser D, Hinterberger W, Geissler D, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia--a randomized phase-III study. Blood. 1997;90(2):590–6.

Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116(1):113–23.

Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology. 2009;18(2):134–43.

Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment–associated cognitive change: an update on the state of the science. Journal of Clinical Oncology. 2012;30(30):3675–86.

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology. 2002;20(2):485–93.

Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J ClinOncol. 2000;18:2695–701.

Von derWeid N, Mosimann I, Hirt A, et al. Intellectual outcome in children and adolescents with acute lymphoblastic leukaemia treated with chemotherapy alone: age- and sex-related differences. Eur J Cancer. 2003;39:359–65.

Castellon SA, Ganz PA, Bower JE, et al. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J. Clin. Exp. Neuropsychol. 2004;26:955–69.

Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34.

Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104(11):2499–507.

AndersonV GT, Smibert E, et al. Neurobehaviouralsequelae following cranial irradiation and chemotherapy in children: an analysis of risk factors. PediatrRehabil. 1997;1:63–76.

Vardy J, Wefel JS, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Annals of Oncology. 2008;19:623–9.

Peckham VC. Learning disorders associated with the treatment of cancer in childhood. Journal of the Association of Pediatric Oncology Nursing. 1988;5:10–3.

Peckham VC. Learning disabilities in long-term survivors of childhood cancer: concerns for parents and teachers. Reading, Writing and Learning Disabilities. 1989;5:313–25.

Loh KP, Janelsins MC, Mohile SG et al. (2016): Chemotherapy-related cognitive impairment in older patients with cancer J Geriatr Oncol. Jul;7(4):270-280.

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.

Panza F, Frisardi V, Capurso C, Imbimbo BP, Vendemiale G, Santamato A, Solfrizzi V. Metabolic syndrome and cognitive impairment: current epidemiology and possible underlying mechanisms. J Alzheimers Dis. 2010;21(3):691–724.

Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, et al.(2012): Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. Apr; 20(4):831–839.

Buizer AI, de Sonneville LM, van den Heuvel-Eibrink MM, et al. Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: Effect of treatment intensity. Pediatr Blood Cancer. 2005;45:281–90.

Schmithorst VJ, Holland SK, Dardzinski BJ. Developmental differences in white matter architecture between boys and girls. Hum Brain Mapp. 2008;29:696–710.

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, LeBlanc S. … for the CHARTER and HNRC Groups. (2011). HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. Journal of Neurovirology. 17(1):3–16.

Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788–93.

Meadows ME, Chang G, Jones JA, Antin JR, Orav EJ. Predictors of neuropsychological change in patients with chronic myelogenous leukemia and myelodysplastic syndrome. Arch Clin Neuropsychol. 2013;28:363–74.

Jones D, Vichaya EG, Wang XS, Sailors MH, Cleeland CS, Wefel JS. Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer. 2013;119:4188–95.

Cheung YT, Lim SR, Ho HK, Chan A. Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. PLoS One. 2013;8(12):e81234.